Lysostaphin: an antistaphylococcal agent
Kumar J K
Applied Microbiology and Biotechnology, 80(4), 555-561 (2008)
R Satishkumar et al.
Nanotechnology, 22(50), 505103-505103 (2011-11-24)
The objective of this paper was to study the effect of antibody-directed targeting of S. aureus by comparing the activities of lysostaphin conjugated to biodegradable polylactide nanoparticles (NPs) in the presence and in the absence of co-immobilized anti-S. aureus antibody....
Thomas S Lawson et al.
Journal of clinical laboratory analysis, 25(5), 359-365 (2011-09-16)
Aspects of the fluorescence in situ hybridization (FISH) method for the detection of clinically important bacteria, such as Staphylococcus aureus, Staphylococcus epidermidis, and Escherichia coli, were investigated for optimization. Various approaches to optimizing the FISH procedure were taken and different...
Igor Belyansky et al.
The American surgeon, 77(8), 1025-1031 (2011-09-29)
Mesh and wound infections during hernia repair are predominantly caused by Staphylococcus aureus. Human acellular dermis (HAD) is known to lose its integrity in the face of large bacterial loads. The goal of this study was to determine if lysostaphin...
Shaw R Gargis et al.
Applied and environmental microbiology, 76(20), 6944-6946 (2010-08-24)
Resistance to lysostaphin, a staphylolytic glycylglycine endopeptidase, is due to a FemABX-like immunity protein that inserts serines in place of some glycines in peptidoglycan cross bridges. These modifications inhibit both binding of the recombinant cell wall targeting domain and catalysis...